Table 2.
Variables for harmonised and cohort-specific analyses
| ALSWH | 45 and Up Study | Rotterdam study | Harmonisable status | ||||
| 1946–1951 Cohort | 1921–1926 Cohort | RS-I-4 | RS-II-2 | RS-III-1 | |||
| Sociodemographic characteristics | |||||||
| Age | Y | Y | Y | Y | Y | Y | Y* |
| Marital status | Y | Y | Y | Y | Y | Y | Y* |
| Country of birth | Y | Y | Y | N | N | N | N |
| Socioeconomic disadvantage | Y | Y | Y | Y | Y | Y | Y* |
| Remoteness | Y | Y | Y | NA | NA | NA | Y* |
| Work status | N | N | Y | Y | Y | Y | N |
| Education status | Y | Y | Y | Y | Y | Y | Y* |
| Lifestyle characteristics | |||||||
| Body mass index (height/weight) | Y | Y | Y | Y | Y | Y | Y* |
| Physical activity | Y | Y | Y | N | N | Y | N |
| Smoking status | Y | N | Y | Y | Y | Y | N |
| Alcohol drinks per week | Y | N | Y | Y | Y | Y | N |
| Shift work at night | Y | N | N | N | N | N | N |
| Clinical characteristics | |||||||
| High BP | Y | Y | Y | Y | Y | Y | Y* |
| Systolic BP/diastolic BP | N | N | N | Y | Y | Y | N |
| Blood cholesterol level | N | N | N | Y | Y | Y | N |
| Diabetes | Y | Y | Y | Y | Y | Y | Y* |
| Heart disease | Y | Y | Y | Y | Y | Y | Y* |
| Stroke | Y | Y | Y | Y | Y | Y | Y* |
| Family history of heart disease | N | N | Y | Y | Y | Y | N |
| Family history of stroke | N | N | Y | Y | Y | Y | N |
| Mastectomy | Y | Y | Y | Y | Y | Y | Y* |
| Reproductive health | |||||||
| Age at menarche | Y | N | N | Y | Y | Y | N |
| Age at menopause | Y | N | Y | Y | Y | Y | N |
| Age when had first child | Y | N | Y | Y | Y | Y | N |
| Number of children | Y | Y | Y | Y | Y | Y | Y* |
| History of hysterectomy/both ovaries removed | Y | Y | Y | Y | Y | Y | Y* |
| Breast feeding | N | N | Y | Y | Y | N | N |
| Healthcare utilisation | |||||||
| Concession status | Y | Y | Y | NA | NA | NA | Y* |
| Mammogram | Y | N | Y | N | N | N | N |
| Hospital admissions | Y | Y | Y | N | N | N | N |
| Specialist/consulting physician attendances | Y | Y | Y | N | N | N | N |
| GPs attendances | Y | Y | Y | N | N | N | N |
| Diagnosis of cancer | |||||||
| A diagnosis/history of invasive breast cancer | Y | Y | Y | Y | Y | Y | Y* |
| A diagnosis/history of non-invasive breast cancer (LCIS, DCIS) | Y | Y | Y | Y | Y | Y | Y* |
| Other cancer | Y | Y | Y | Y | Y | Y | Y* |
| Medicine use | |||||||
| CCB | Y | Y | Y | Y | Y | Y | Y* |
| Non-CCB (ACEI, ARB, BB, diuretics, others) | Y | Y | Y | Y | Y | Y | Y* |
| Statins | Y | Y | Y | Y | Y | Y | Y* |
| Current use of combined hormonal contraception | Y | Y | Y | Y | Y | Y | Y* |
| Current use of combined menopausal hormone therapy | Y | Y | Y | Y | Y | Y | Y* |
| Comorbidity (Rx-Risk) score | Y | Y | Y | Y | Y | Y | Y* |
| Mortality | |||||||
| Death | Y | Y | Y | Y | Y | Y | Y* |
This table includes all potential confounders available from ALSWH (https://alswh.org.au/for-data-users/data-documentation/data-dictionary/), 45 and Up Study (https://www.saxinstitute.org.au/solutions/45-and-up-study/use-the-45-and-up-study/data-and-technical-information/), and Rotterdam Study (https://www.erasmusmc.nl/en/research/core-facilities/ergo-the-rotterdam-study).
*These variables will be used in the harmonised analysis.
†Comorbidity (Rx-Risk) score includes 46 clinical conditions based on prescribed medicine claims data.
ACEI, ACE inhibitors; ALSWH, Australian Longitudinal Study on Women’s Health; ARB, angiotensin receptor blockers; BB, beta blockers; BP, blood pressure; CCB, calcium channel blockers; CVD, cardiovascular disease; DCIS, ductal carcinoma in situ; FNA, fine-needle aspiration; LCIS, lobular carcinoma in situ; N, no data available; NA, not applicable; Y, Yes, data available.